

# Regulation of *MMP13* by antitumor *microRNA-375* markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma

YUSAKU OSAKO<sup>1</sup>, NAOHIKO SEKI<sup>2</sup>, YOSHIAKI KITA<sup>1</sup>, KEIICHI YONEMORI<sup>1</sup>, KEIICHI KOSHIZUKA<sup>2</sup>, AKIRA KUROSUMI<sup>2</sup>, ITARU OMOTO<sup>1</sup>, KEN SASAKI<sup>1</sup>, YASUTO UCHIKADO<sup>1</sup>, HIROSHI KURAHARA<sup>1</sup>, KOSEI MAEMURA<sup>1</sup> and SHOJI NATSUGOE<sup>1</sup>

<sup>1</sup>Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical Sciences, Kagoshima University, Sakuragaoka, Kagoshima 890-8520; <sup>2</sup>Department of Functional Genomics, Chiba University Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan

Received August 8, 2016; Accepted September 28, 2016

DOI: 10.3892/ijo.2016.3745

**Abstract.** Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignancies. Recently developed molecular targeted therapies are not available for patients with ESCC. After curative surgical resection, patients frequently suffer distant metastasis and recurrence. Exploration of novel ESCC metastatic pathways may lead to the development of new treatment protocols for this disease. Accordingly, we have sequentially identified microRNA (miRNA)-mediated metastatic pathways in several cancers. Our past studies of miRNA expression signatures have shown that *microRNA-375* (*miR-375*) is frequently reduced in several types of cancers, including ESCC. In the present study, we aimed to investigate novel *miR-375*-mediated metastatic pathways in ESCC cells. The expression of *miR-375* was downregulated in ESCC tissues, and ectopic expression of this miRNA markedly inhibited cancer cell migration and invasion, suggesting that *miR-375* acted as an antimetastatic miRNA in ESCC cells. Our strategies for miRNA target searching demonstrated that matrix metalloproteinase 13 (*MMP13*) was directly regulated by *miR-375* in ESCC cells. Overexpression of *MMP13* was observed in ESCC clinical tissues, and the expression of *MMP13* promoted cancer cell aggressiveness. Moreover, oncogenic genes, including *CENPF*, *KIF14* and *TOP2A*, were shown to be regulated downstream of *MMP13*. Taken together, these findings demonstrated that the antitumor *miR-375*/oncogenic *MMP13* axis had a pivotal role in ESCC aggressiveness.

These results provide novel insights into the potential mechanisms of ESCC pathogenesis.

## Introduction

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive cancers and the major histological type of esophageal cancer in Japan and East Asia (1-3). ESCC cells frequently metastasize to the lymph nodes, liver, lungs and bone (2-4). Despite the use of multimodality therapies, the prognosis of patients with ESCC is still poor, with an overall 5-year survival rate of approximately 20-30% (2,4). Recently developed molecularly targeted therapeutics have not been shown to have beneficial effects in patients with ESCC (2). Additionally, the molecular pathogenesis of the aggressive phenotype in ESCC remains unclear. Thus, in order to improve disease outcomes in patients with ESCC, it is necessary to elucidate the molecular mechanisms of ESCC cell aggressiveness using advanced genomic approaches.

The discovery of microRNAs (miRNAs) has resulted in major advancements in cancer research (5,6). miRNAs are small non-coding RNAs that function to fine tune the expression of protein coding/non-coding RNAs by repressing translation or cleaving RNA transcripts in a sequence-dependent manner (7). The unique characteristic function of miRNAs is to regulate RNA transcripts in human cells. Therefore, dysregulated expression of miRNAs can disrupt tightly regulated RNA networks in cancer cells. Currently, numerous studies have shown that miRNAs are aberrantly expressed in several cancers, including ESCC (6,8). Using miRNA expression signature analyses, we have sequentially identified tumor-suppressive miRNAs and shown that these miRNAs mediate novel cancer networks (9-13).

Our miRNA expression signatures revealed that *microRNA-375* (*miR-375*) is frequently downregulated in several types of squamous cell carcinoma (10,13,14). Moreover, our previous studies demonstrated that ectopic expression of *miR-375* suppressed cancer cell aggressiveness in several types of cancer cells (15). In ESCC cells, several studies have

---

*Correspondence to:* Dr Naohiko Seki, Department of Functional Genomics, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan  
E-mail: naoseki@faculty.chiba-u.jp

**Key words:** microRNA, miR-375, esophageal squamous cell carcinoma, matrix metalloproteinase 13, tumor suppressor

Table I. Clinical features of patients with ESCC.

No.	Age (years)	Gender	Differentiation	T	N	M	Stage	ly	v	Recurrence
1	68	Male	Poor	1b	2	0	IIIA	1	3	+
2	72	Male	Moderate	1b	0	0	IA	0	1	-
3	69	Male	Moderate	1b	0	0	IIIA	0	0	-
4	62	Male	Well	3	2	0	IIIB	1	1	+
5	66	Male	Moderate	3	0	0	IIA	1	1	-
6	74	Male	Moderate	2	2	0	IIIA	3	1	+
7	56	Male	Moderate	2	0	0	IB	0	1	-
8	79	Male	Moderate	2	1	0	IIB	1	1	-
9	68	Male	Moderate	1b	2	0	IIIA	1	1	-
10	52	Male	Poor	1b	0	0	IA	1	1	+
11	67	Male	Well	3	2	0	IIIB	2	2	+
12	57	Male	Poor	3	3	0	IIIC	1	1	+
13	70	Male	Moderate	3	0	0	IIA	1	1	+
14	66	Male	Moderate	3	0	0	IIA	1	1	-
15	63	Male	Well	3	3	0	IIIC	2	1	+
16	55	Male	Moderate	3	2	0	IIIB	1	1	+
17	60	Male	Well	1b	1	0	IIB	1	1	-
18	78	Male	Well	3	0	0	IIA	1	2	-
19	71	Male	Well	3	0	0	IIA	1	2	-
20	75	Male	Moderate	3	2	0	IIIB	1	1	+
21	60	Male	Moderate	2	1	0	IIB	1	2	-
22	62	Male	Well	1a	1	0	IIB	0	0	-
23	71	Male	Moderate	1b	1	0	IIB	0	0	-
24	69	Male	Moderate	1b	0	0	IA	1	0	-
25	84	Male	Well	2	1	0	IIB	1	1	-

indicated that *miR-375* has antitumor roles through targeting oncogenic genes (16,17). Moreover, *miR-375*-mediated cancer pathways are essential for cancer cell initiation, development and aggressiveness.

Accordingly, in the present study, we aimed to investigate the novel cancer networks regulated by *miR-375* in ESCC cells. Our present data showed that matrix metalloproteinase 13 (*MMP13*) was directly regulated by *miR-375* in ESCC cells. Overexpression of *MMP13* was observed in ESCC clinical tissues, and knockdown of *MMP13* expression markedly inhibited ESCC cell migration and invasion, indicating that *MMP13* acted as a cancer-promoting gene in ESCC cells. Moreover, the oncogenic genes *CENPF*, *KIF14* and *TOP2* were found to function downstream of *MMP13*. Taken together, these results showed that the antitumor *miR-375*/oncogenic *MMP13* axis had a pivotal role in ESCC aggressiveness.

## Materials and methods

**Clinical ESCC specimens and ESCC cell lines.** Clinical specimens were collected from 25 patients with ESCC. All patients underwent primary surgical treatment and were pathologically proven to have ESCC at the Kagoshima University Hospital from 2010 to 2014. The present study was approved by the Bioethics Committee of Kagoshima University; written

prior informed consent and approval were obtained from all patients. The clinicopathological characteristics of the patients are shown in Table I.

We used two ESCC cell lines: TE-8, which was moderately differentiated; and TE-9, which was poorly differentiated. Both of these cell lines were provided by Riken BioResource Center (Tsukuba, Japan).

Extraction of total RNA from clinical specimens and cell lines was performed using ISOGEN (Nippon Gene, Tokyo, Japan) according to the manufacturer's protocol. The quality of RNA was checked using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

**Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR).** The procedure for PCR quantification was previously described (13,18-20). The expression levels of *miR-375* (assay ID: 000564; Applied Biosystems, Foster City, CA, USA) were analyzed by TaqMan qRT-PCR assays (TaqMan MicroRNA assays; Applied Biosystems) and *RNU48* (assay ID: 001006) was used for normalization. TaqMan probes and primers for *MMP-13* (assay ID: Hs00233992\_m1; Applied Biosystems), *CENPF* (assay ID: Hs01118845\_m1), *KIF14* (assay ID: Hs00978236\_m1) and *GUSB* (the internal control; assay ID: Hs00939627\_m1; Applied Biosystems) were used for gene expression analysis.




Figure 1. Expression levels of *miR-375* and functional assays of *miR-375* transfection in ESCC cell lines. (A) Expression levels of *miR-375* in ESCC or normal esophageal tissues and ESCC cell lines. (B) Cell proliferation was determined by XTT assays. \* $P < 0.0001$ , \*\* $P < 0.05$ . (C) Cell migration activity was determined by migration assays. (D) Cell invasion activity was determined by Matrigel invasion assays.

*Transfection with mature miRNAs and small interfering RNAs (siRNAs).* The following mature miRNA was used: Ambion Pre-miR miRNA precursor for *hsa-miR-375* (product ID: PM10327; Applied Biosystems). The following siRNAs were used: Stealth Select RNAi siRNA, *si-MMP13* (cat nos. HSS106637 and HSS106638; Invitrogen, Carlsbad, CA, USA), and negative control miRNA/siRNA (P/N: AM17111; Applied Biosystems). RNAs were incubated with Opti-MEM (Invitrogen) and Lipofectamine RNAiMax transfection reagent (Invitrogen), as previously described (13,18-20).

*Cell proliferation, migration and invasion assays.* TE-8 and TE-9 cells were transfected with 10 nM miRNAs or siRNAs by reverse transfection. Cell proliferation, migration and invasion assays were performed as previously described (13,18-20).

*Screening of miR-375 target genes using in silico analysis and gene expression data.* To identify *miR-375* target genes, a combination of genome-wide gene expression and *in silico* analyses was conducted as previously described (13,18-20). The microarray data were deposited into the GEO repository under accession number GSE77790. Next, we selected putative miRNA target genes using microRNA.org (August, 2010 release, <http://www.microrna.org>) databases. Our strategy for identification of *miR-375* target genes is shown in Fig. 2.

*Western blot analysis.* Anti-human MMP-13 rabbit polyclonal IgG (1:1,000; sc30073; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as a primary antibody. Anti-human GAPDH mouse monoclonal IgG (1:5,000; 010-25521; Wako Pure Chemical Industries, Osaka, Japan) was used as an internal loading control. The membrane was washed and incubated with a horseradish peroxidase-conjugated secondary

antibody. Bands were visualized using Amersham ECL Prime Western Blotting detection reagent (GE Healthcare Life Sciences, Uppsala, Sweden).

*Immunohistochemistry.* Tumor samples were fixed with 10% formaldehyde in phosphate-buffered saline (PBS), embedded in paraffin and sectioned into 4- $\mu$ m-thick slices. The sections were incubated with rabbit polyclonal anti-MMP-13 IgG (1:200; ab84594; Abcam, Cambridge, UK) at 4°C overnight. The procedure for immunohistochemistry was previously described (21).

*Plasmid construction and Dual-luciferase reporter assays.* Partial wild-type sequences of the 3' untranslated region (UTR) of *MMP13* containing the *miR-375* target site (positions 100-113 of the *MMP13* 3' UTR) or sequences with a deleted *miR-375* target site were inserted between the *XhoI* and *PmeI* restriction sites in the 3' UTR of the *hRluc* gene in the psiCHECK-2 vector (product ID: C8021; Promega, Madison, WI, USA). TE-8 and TE-9 cells were transfected with 50 ng of the vector and 10 nM *miR-375* using Lipofectamine 2000 (Thermo Fisher Scientific) in Opti-MEM (Thermo Fisher Scientific). The activities of firefly and *Renilla* luciferases were determined in lysates of transfected cells using a Dual-luciferase reporter assay system according to the manufacturer's recommendations (product ID: E1960; Promega). Data were normalized to firefly luciferase activity (ratio of *Renilla*/firefly luciferase activities).

*Identification of downstream genes mediated by MMP13 in ESCC cells.* Gene expression analyses of *si-MMP13*-transfected TE-8 and TE-9 cells revealed molecular targets mediated by *MMP13* in ESCC cells. This method is described in more detail in previous studies (13,18-20). Microarray

Table II. Highly expressed genes putatively regulated by *miR-375* in ESCC.

Entrez Gene ID	Gene symbol	Description	<i>miR-375</i> target sites	Expression in <i>miR-375</i> transfectants		GEO data (GSE20347) FC (Log <sub>2</sub> )
				TE-8	TE-9	
4322	<i>MMP13</i>	Matrix metalloproteinase 13	1	-2.24	-1.76	5.12
6004	<i>RGS16</i>	Regulator of G-protein signaling 16	3	-1.50	-0.92	2.45
4920	<i>ROR2</i>	Receptor tyrosine kinase-like orphan receptor 2	1	-0.80	-0.59	2.14
10202	<i>DHRS2</i>	Dehydrogenase/reductase (SDR family) member 2	3	-3.07	-0.83	2.02
1956	<i>EGFR</i>	Epidermal growth factor receptor	1	-0.93	-0.78	1.58
655	<i>BMP7</i>	Bone morphogenetic protein 7	1	-0.85	-0.74	1.54
23363	<i>OBSL1</i>	Obscurin-like 1	1	-0.80	-0.71	1.52
23035	<i>PHLPP2</i>	PH domain and leucine rich repeat protein phosphatase 2	1	-0.69	-0.64	1.15
1896	<i>EDA</i>	Ectodysplasin A	1	-0.72	-0.63	1.09

results were deposited in the GEO database (accession number GSE82108).

**Statistical analysis.** Relationships between two or three variables and numerical values were analyzed using the Mann-Whitney U test or the Bonferroni-adjusted Mann-Whitney test. Spearman's rank test was used to evaluate the correlations between the expression levels of *miR-375* and *MMP13*. Expert StatView version 5.0 (SAS Institute, Inc., Cary, NC, USA) was used in these analyses.


## Results

**Expression levels of *miR-375* in ESCC clinical specimens and cell lines.** We evaluated the expression levels of *miR-375* in ESCC tissues (n=25), normal esophageal specimens (n=13), and ESCC cell lines (TE-8 and TE-9). The patient backgrounds and clinicopathological characteristics are shown in Table I. The expression levels of *miR-375* were significantly downregulated in cancer tissues and ESCC cell lines compared with those in normal tissues (P<0.0001; Fig. 1A). Additionally, there were no significant relationships between the expression level of *miR-375* and any of the clinicopathological parameters examined in this study (recurrence, T stage, N stage, vascular invasion, or survival rate).

**Effects of *miR-375* restoration on cell proliferation, migration and invasion in ESCC cell lines.** To investigate the antitumor functions of *miR-375*, we performed gain-of-function studies using mature miRNA transfection of TE-8 and TE-9 cells.

Cell proliferation was significantly suppressed by *miR-375* transfection in TE-9 cells in comparison with that of mock or miR-control transfectants (Fig. 1B). However, no changes were detected in TE-8 cells (Fig. 1B).

Migration assays showed that cell migration activity was significantly inhibited by *miR-375* transfection in TE-8 and TE-9 cells in comparison with that in mock or miR-control transfectants (Fig. 1C). Additionally, Matrigel invasion assays

Figure 2. The strategy for analysis of *miR-375* target genes.

demonstrated that cell invasion activity was significantly inhibited by *miR-375* transfection in TE-8 and TE-9 cells in comparison with that in mock or miR-control transfectants (Fig. 1D).

**Identification of putative target genes regulated by *miR-375* in ESCC cells.** To gain additional insights into the molecular pathways regulated by antitumor *miR-375* in ESCC cells, we used a combination of *in silico* and gene expression analyses. The strategy for identification of the *miR-375*-regulated genes in ESCC cells is shown in Fig. 2.




Figure 3. Expression levels of *MMP13* mRNA and immunohistochemical staining of MMP13 protein in ESCC specimens. (A) Expression levels of *MMP13* mRNA in ESCC or normal esophageal tissues and ESCC cell lines. (B) The expression of *miR-375* and *MMP13* mRNA was negatively correlated ( $r = -0.661$  and  $P < 0.0001$ ). (C) Immunohistochemical staining of *MMP13* in ESCC specimens. All ESCC tissues were stained positively, whereas normal esophageal tissues were stained negatively or weakly (left panel, MMP13 staining; right panel, hematoxylin-eosin staining; original magnification, x200).

In gene expression analyses, 2,897 and 1,007 genes were downregulated ( $\log_2$  ratio  $< -0.5$ ) in TE-8 and TE-9 *miR-375* transfectants, respectively, in comparison with that in control transfectants. Our present expression data were deposited in the Gene Expression Omnibus (GEO accession number GSE77790). Among these downregulated genes, we searched for genes having putative *miR-375* binding sites in their 3' UTRs using the microRNA.org database. A total of 55 genes were identified as putative target genes of *miR-375*, and nine genes were upregulated in ESCC clinical specimens, as determined using ESCC expression data (GEO accession number: GSE20347; Table II).

In this study, we focused on *MMP13* because its expression was most upregulated in ESCC clinical specimens and most downregulated in *miR-375* transfectants. Moreover, previous studies have shown that the activation of MMPs is associated with cancer cell aggressiveness (22).

*Expression of MMP13 in ESCC clinical specimens.* Next, we validated the upregulation of *MMP13* in the ESCC clinical specimens at both the mRNA and the protein levels. The expression of *MMP13* was significantly upregulated in 25 ESCC specimens and ESCC cell lines compared with that in 13 normal specimens ( $P < 0.0001$ ; Fig. 3A). The




Figure 4. Direct regulation of *MMP13* by *miR-375* in ESCC cell lines. (A) Expression levels of *MMP13* mRNA 72 h after transfection with *miR-375*. (B) *MMP13* protein expression 72 h after transfection with *miR-375*. (C) Putative *miR-375* binding sites in the 3' UTR of *MMP13* mRNA. (D) Luciferase reporter assay using vectors encoding putative *miR-375* target sites at positions 100-113 for both wild-type and deletion-type constructs. *Renilla* luciferase values were normalized to firefly luciferase values. \* $P < 0.0001$ , \*\* $P < 0.05$ .

Spearman's rank tests showed negative correlations between the expression of *miR-375* and that of *MMP13* ( $r = -0.661$ ,  $P < 0.0001$ ; Fig. 3B).

Immunohistochemistry showed that *MMP13* tended to be strongly expressed in ESCC lesions, whereas low expression was observed in normal esophageal epithelium (Fig. 3C).

*Direct regulation of MMP13 by miR-375 in ESCC cells.* We performed qRT-PCR to validate *miR-375*-mediated repression of *MMP13* expression in ESCC cell lines. Our results showed that *MMP13* mRNA was significantly reduced in *miR-375*




Figure 5. Loss of function studies using siRNAs. (A) Expression levels of *MMP13* mRNA after transfection with *si-MMP13* in ESCC cell lines. (B) *MMP13* protein expression 72 h after transfection with *si-MMP13*. (C) Cell proliferation was determined by XTT assays. Inhibition of cell proliferation was observed in *si-MMP13*-transfected cell lines. (D) Cell migration activity was determined by migration assays. (E) Cell invasion was determined by Matrigel invasion assays. Inhibition of migration and invasion was observed in *si-MMP13*-transfected cell lines. \* $P < 0.0001$ .




Figure 6. The strategy for analysis of *MMP13* downstream genes.

transfectants in comparison with that in mock or miR-control transfectants ( $P < 0.0001$ ; Fig. 4A). *MMP13* protein expression was also repressed in *miR-375* transfectants (Fig. 4B).

Next, we performed luciferase reporter assays using TE-8 and TE-9 cells to determine whether *MMP13* had an actual target site for *miR-375* binding. The microRNA.org database predicted that there was one putative target site in the 3' UTR of *MMP13* (Fig. 4C). Compared with the miR-control, luminescence intensity was significantly reduced by transfection with *miR-375* at the *miR-375* target site, positions 100-113, in the 3' UTR of *MMP13* (Fig. 4D).

**Effects of silencing *MMP13* on proliferation, migration and invasion in ESCC cells.** To investigate the functional roles of *MMP13* in ESCC cell lines, we performed loss-of-function assays by transfection of *si-MMP13* into TE-8 and TE-9 cells.

First, we evaluated the knockdown efficiency of *si-MMP13* transfection in ESCC cell lines. In the present study, we used two siRNAs targeting *MMP13* (*si-MMP13-1* and *si-MMP13-2*). According to qRT-PCR and western blot analyses, both siRNAs effectively downregulated *MMP13* expression in both cell lines (Fig. 5A and B).

Cell proliferation, migration and invasion assays demonstrated that cell proliferation, migration, and invasion were inhibited in *si-MMP13*-transfected cells compared with those in mock- or siRNA-control-transfected cells (Fig. 5C-E).

**Identification of downstream genes regulated by *MMP13* in ESCC cells.** To determine which downstream genes were regulated by *MMP13*, genome-wide gene expression and *in silico* analyses were performed in TE-8 and TE-9 cells transfected with *si-MMP13*.

Our expression analysis showed that a total of 298 genes were commonly downregulated ( $\log_2$  ratio  $< -2.0$ ) in TE-8 and TE-9 cells following *si-MMP13* transfection. Among these genes, 52 were upregulated in ESCC clinical specimens, as determined using ESCC expression data (GEO accession number: GSE20347; Fig. 6 and Table III).




Figure 7. mRNA expression levels of *MMP13* downstream genes (*CENPF* and *KIF14*) in ESCC specimens. (A and C) Expression levels of *CENPF* and *KIF14* mRNA in ESCC or normal esophageal tissues and ESCC cell lines. (B and D) The expression levels of *MMP13/CENPF* and *MMP13/KIF14* mRNAs were positively correlated ( $P < 0.0001$ ).

We then validated the upregulation of *CENPF* and *KIF14* mRNAs in ESCC clinical specimens. The expression of *CENPF* and *KIF14* mRNAs was significantly upregulated in 25 ESCC specimens and ESCC cell lines compared with that in 13 normal specimens ( $P < 0.0001$ ; Fig. 7A and C). The Spearman's rank tests showed correlations between the expression of *MMP13* and that of *CENPF* or *KIF14* (*CENPF*:  $r = 0.554$ ,  $P = 0.0007$ , Fig. 7B; *KIF14*:  $r = 0.729$ ,  $P < 0.0001$ , Fig. 7D).

Table III. Downregulated genes in *si-MMP13*-transfected ESCC cell lines.

Entrez gene ID	Gene symbol	Description	Expression in <i>si-MMP13</i> transfectants FC (log <sub>2</sub> )		GEO data (GSE20347) FC (log <sub>2</sub> )
			TE8	TE9	
4322	<i>MMP13</i>	Matrix metalloproteinase 13 (collagenase 3)	-4.42	-4.47	5.12
1063	<i>CENPF</i>	Centromere protein F, 350/400 kDa	-2.96	-5.18	2.31
9928	<i>KIF14</i>	Kinesin family member 14	-2.28	-4.66	2.14
2842	<i>GPR19</i>	G protein-coupled receptor 19	-2.67	-3.74	2.12
983	<i>CDK1</i>	Cyclin-dependent kinase 1	-2.07	-3.78	1.95
55165	<i>CEP55</i>	Centrosomal protein 55 kDa	-3.33	-4.79	1.94
1033	<i>CDKN3</i>	Cyclin-dependent kinase inhibitor 3	-2.08	-3.73	1.94
7153	<i>TOP2A</i>	Topoisomerase (DNA) II alpha 170 kDa	-3.36	-5.01	1.91
10403	<i>NDC80</i>	NDC80 kinetochore complex component	-2.19	-3.69	1.76
9787	<i>DLGAP5</i>	Discs, large ( <i>Drosophila</i> ) homolog-associated protein 5	-2.27	-3.32	1.72
55215	<i>FANCI</i>	Fanconi anemia, complementation group I	-2.27	-3.97	1.70
23306	<i>TMEM194A</i>	Transmembrane protein 194A	-2.31	-2.79	1.68
4751	<i>NEK2</i>	NIMA-related kinase 2	-2.70	-3.84	1.66
2735	<i>GLI1</i>	GLI family zinc finger 1	-2.70	-3.31	1.63
3161	<i>HMMR</i>	Hyaluronan-mediated motility receptor (RHAMM)	-4.06	-5.29	1.60
259266	<i>ASPM</i>	Asp (abnormal spindle) homolog, microcephaly associated ( <i>Drosophila</i> )	-2.17	-3.81	1.56
4998	<i>ORC1</i>	Origin recognition complex, subunit 1	-2.23	-3.08	1.53
57405	<i>SPC25</i>	SPC25, NDC80 kinetochore complex component	-2.16	-4.12	1.48
28951	<i>TRIB2</i>	Tribbles pseudokinase 2	-2.28	-2.35	1.44
9603	<i>NFE2L3</i>	Nuclear factor, erythroid 2-like 3	-2.00	-2.51	1.42
9638	<i>FEZ1</i>	Fasciculation and elongation protein zeta 1 (zygin I)	-2.27	-2.97	1.42
9918	<i>NCAPD2</i>	Non-SMC condensin I complex, subunit D2	-2.12	-2.79	1.38
7468	<i>WHSC1</i>	Wolf-Hirschhorn syndrome candidate 1	-2.43	-3.36	1.33
100288413	<i>ERVMER34-1</i>	Endogenous retrovirus group MER34, member 1	-2.76	-3.78	1.32
1062	<i>CENPE</i>	Centromere protein E, 312 kDa	-2.60	-3.91	1.29
55063	<i>ZCWPW1</i>	Zinc finger, CW type with PWWP domain 1	-3.19	-3.44	1.25
81624	<i>DIAPH3</i>	Diaphanous-related formin 3	-2.22	-3.54	1.25
6119	<i>RPA3</i>	Replication protein A3, 14 kDa	-2.34	-3.42	1.24
8318	<i>CDC45</i>	Cell division cycle 45	-2.13	-4.07	1.23
64151	<i>NCAPG</i>	Non-SMC condensin I complex, subunit G	-3.25	-3.92	1.22
7083	<i>TK1</i>	Thymidine kinase 1, soluble	-2.11	-3.86	1.22
55732	<i>C1orf112</i>	Chromosome 1 open reading frame 112	-2.06	-2.62	1.22
1058	<i>CENPA</i>	Centromere protein A	-2.02	-3.86	1.18
55635	<i>DEPDC1</i>	DEP domain containing 1	-2.33	-3.44	1.18
3925	<i>STMN1</i>	Stathmin 1	-2.66	-4.51	1.17
3092	<i>HIP1</i>	Huntingtin interacting protein 1	-2.71	-3.51	1.17
5427	<i>POLE2</i>	Polymerase (DNA directed), epsilon 2, accessory subunit	-2.18	-4.37	1.15
1719	<i>DHFR</i>	Dihydrofolate reductase	-2.46	-3.63	1.14
54830	<i>NUP62CL</i>	Nucleoporin 62 kDa C-terminal like	-2.17	-2.22	1.10
5062	<i>PAK2</i>	p21 protein (Cdc42/Rac)-activated kinase 2	-2.37	-2.60	1.09
100129361	<i>LOC100129361</i>	Chromosome X open reading frame 69-like	-2.57	-2.46	1.09
5933	<i>RBL1</i>	Retinoblastoma-like 1	-3.24	-4.43	1.08
4288	<i>MKI67</i>	Marker of proliferation Ki-67	-2.14	-4.87	1.03
81691	<i>LOC81691</i>	Exonuclease NEF-sp	-2.62	-3.61	1.03
675	<i>BRCA2</i>	Breast cancer 2, early onset	-2.90	-4.04	1.00



## Discussion

Numerous studies of miRNA expression signatures in ESCC have shown that *miR-375* is frequently downregulated in cancer tissues and functions as an antitumor miRNA (14,23). In the present study, we confirmed that *miR-375* was markedly downregulated in cancer tissues and that ectopic expression of *miR-375* significantly suppressed cancer cell migration and invasion. Thus, we found that loss of *miR-375* expression enhanced cancer cell aggressiveness in ESCC. Many previous studies have shown that the expression of *miR-375* is markedly decreased in several types of cancers and that *miR-375* functions as an antitumor miRNA (15,24). In contrast to these antitumor activities, *miR-375* is upregulated in pediatric acute myeloid leukemia (AML) and prostate cancer, suggesting that *miR-375* acts as an oncogenic miRNA in these diseases (25,26). The dual function of *miR-375* is very unique; thus, it is important to identify *miR-375*-regulated pathways in various cancer types.

It is also important to elucidate novel RNA networks regulated by antitumor *miR-375* in ESCC cells. Previous studies have shown that insulin-like growth factor 1 receptor (*IGF1R*), lactate dehydrogenase B (*LDHB*), and astrocyte elevated gene-1/metadherin (*AEG-1/MTDH*) are directly regulated by *miR-375* in ESCC cells (16,17). These target genes are upregulated in ESCC clinical specimens and functioned as oncogenes in this disease. Another unique characteristic of miRNAs is that a single miRNA can regulate a large number of RNA transcripts in human cells (27,28). Thus, the continuous identification of *miR-375*-regulated oncogenes in ESCC cells is important for elucidation of the molecular pathogenesis of ESCC.

In this study, we identified *MMP13* as a direct target of antitumor *miR-375* in ESCC cells. *MMP13* (also known as collagenase 3) is a member of the collagenase subfamily of MMPs and functions to degrade a wide range of extracellular matrix components, including tenascin C, fibronectin and type I-IV collagen (29). Thus, *MMP13* has a wide range of proteolytic functions, suggesting that *MMP13* is involved in several physiological and pathological processes (30). High expression of *MMP13* has been reported in rheumatoid arthritis, osteoarthritis and several types of cancers (22). Previous studies have also shown that high expression of *MMP13* is associated with vascular invasion and lymph node metastasis in ESCC (31). Our present data demonstrated that knockdown of *MMP13* markedly reduced cancer cell migration and invasion in ESCC cells.

The *MMP13* gene has also been reported to be epigenetically regulated by several other miRNAs, including *miR-125b* and *miR-143*, in cancer cells (32-34). Notably, our miRNA signatures have shown that *miR-125b* and *miR-143* are downregulated in ESCC and in oral and hypopharyngeal squamous cell carcinoma (12-14). Moreover, functional assays have indicated that these miRNAs act as tumor suppressors in several cancers, including ESCC cells (32-35). Loss of the expression of several antitumor miRNAs and activation of *MMP13* may enhance cancer cell aggressiveness and metastasis. Thus, identification of *miR-375/MMP13*-mediated cancer pathways may facilitate the discovery of candidate therapeutic targets in ESCC.

Based on the above, we further investigated the downstream genes mediated by *MMP13* in ESCC cells using genome-wide gene expression analysis. Our data showed that several centromere-associated proteins were regulated by *MMP13*-mediated genes, such as *CENPF*, *CENPE*, *CENPA*, *CEP55*, *NDC80* and *SPC25*. Moreover, cell cycle-promoting genes, e.g., *KIF14*, *CDK1*, *TOP2A*, *CDC45* and *PAK2*, were also downregulated by *si-MMP13* in this study. Recent studies have reported that several genes encoding mitotic apparatus components are upregulated in cancer cells and contribute to cancer cell phenotypes (36,37). Therefore, overexpression of genes encoding mitotic apparatus components may represent a potential target for cancer drug development (38). Several compounds that inhibit centromere proteins and mitotic kinesins are being tested as potential cancer therapies in clinical trials (39).

Among these genes, we validated the overexpression of *CENPF* and *KIF14* in ESCC clinical specimens. Previous studies have shown that *CENPF* is a master regulator of prostate cancer malignancy and that high expression of *CENPF* is a prognostic indicator of poor survival and metastasis in patients with ESCC (40). *KIF14* is a member of the kinesin superfamily of proteins and functions as a microtubule motor protein involved in cytokinesis and chromosome segregation (41). Overexpression of *KIF14* has been reported in several cancers, and its expression is associated with cancer cell phenotypes (42,43). An in-depth functional analysis of these genes in ESCC cells is necessary to further characterize these pathways. Identification of the downstream genes regulated by the *miR-375/MMP13* axis may lead to a better understanding of ESCC aggressiveness.

In conclusion, downregulation of *miR-375* was frequently observed in ESCC clinical specimens, and *miR-375* was shown to function as an antitumor miRNA in ESCC cells. To the best of our knowledge, this is the first report demonstrating that *MMP13* is directly regulated by antitumor *miR-375* and acts to regulate several cell cycle promoting genes. The identification of novel molecular pathways and targets regulated by the *miR-375/MMP13* axis may lead to a better understanding of ESCC molecular pathogenesis.

## Acknowledgements

We wish to thank the Joint Research Laboratory, Kagoshima University Graduate School of Medical and Dental Sciences, for the use of their facilities. The present study was supported by KAKENHI (C) grant 15K10801.

## References

- Hongo M, Nagasaki Y and Shoji T: Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. *J Gastroenterol Hepatol* 24: 729-735, 2009.
- Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. *Lancet* 381: 400-412, 2013.
- Ohashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y and Muto M: Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. *Gastroenterology* 149: 1700-1715, 2015.
- Enzinger PC and Mayer RJ: Esophageal cancer. *N Engl J Med* 349: 2241-2252, 2003.
- Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. *Nature* 435: 834-838, 2005.

6. Calin GA and Croce CM: MicroRNA signatures in human cancers. *Nat Rev Cancer* 6: 857-866, 2006.
7. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell* 116: 281-297, 2004.
8. Harada K, Baba Y, Ishimoto T, Shigaki H, Kosumi K, Yoshida N, Watanabe M and Baba H: The role of microRNA in esophageal squamous cell carcinoma. *J Gastroenterol* 51: 520-530, 2016.
9. Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki N: miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). *Br J Cancer* 103: 877-884, 2010.
10. Nohata N, Hanazawa T, Kikkawa N, Sakurai D, Fujimura L, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nakagawa M, *et al*: Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma. *Br J Cancer* 105: 833-841, 2011.
11. Nohata N, Hanazawa T, Kinoshita T, Inamine A, Kikkawa N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Okamoto Y, *et al*: Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma. *Br J Cancer* 108: 1648-1658, 2013.
12. Fukumoto I, Kinoshita T, Hanazawa T, Kikkawa N, Chiyomaru T, Enokida H, Yamamoto N, Goto Y, Nishikawa R, Nakagawa M, *et al*: Identification of tumour suppressive microRNA-451a in hypopharyngeal squamous cell carcinoma based on microRNA expression signature. *Br J Cancer* 111: 386-394, 2014.
13. Fukumoto I, Hanazawa T, Kinoshita T, Kikkawa N, Koshizuka K, Goto Y, Nishikawa R, Chiyomaru T, Enokida H, Nakagawa M, *et al*: MicroRNA expression signature of oral squamous cell carcinoma: Functional role of microRNA-26a/b in the modulation of novel cancer pathways. *Br J Cancer* 112: 891-900, 2015.
14. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. *Int J Cancer* 127: 2804-2814, 2010.
15. Kinoshita T, Hanazawa T, Nohata N, Okamoto Y and Seki N: The functional significance of microRNA-375 in human squamous cell carcinoma: Aberrant expression and effects on cancer pathways. *J Hum Genet* 57: 556-563, 2012.
16. Isozaki Y, Hoshino I, Nohata N, Kinoshita T, Akutsu Y, Hanari N, Mori M, Yoneyama Y, Akanuma N, Takeshita N, *et al*: Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma. *Int J Oncol* 41: 985-994, 2012.
17. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, Qin YR and Guan XY: MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. *Gut* 61: 33-42, 2012.
18. Matsushita R, Yoshino H, Enokida H, Goto Y, Miyamoto K, Yonemori M, Inoguchi S, Nakagawa M and Seki N: Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell aggressiveness. *Oncotarget* 7: 28460-28487, 2016.
19. Goto Y, Kojima S, Nishikawa R, Kurozumi A, Kato M, Enokida H, Matsushita R, Yamazaki K, Ishida Y, Nakagawa M, *et al*: MicroRNA expression signature of castration-resistant prostate cancer: The microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. *Br J Cancer* 113: 1055-1065, 2015.
20. Goto Y, Kojima S, Nishikawa R, Enokida H, Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T and Seki N: The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. *Oncotarget* 5: 7748-7759, 2014.
21. Kita Y, Nishizono Y, Okumura H, Uchikado Y, Sasaki K, Matsumoto M, Setoyama T, Tanoue K, Omoto I, Mori S, *et al*: Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma. *Oncol Rep* 31: 1986-1992, 2014.
22. Brinckerhoff CE, Rutter JL and Benbow U: Interstitial collagenases as markers of tumor progression. *Clin Cancer Res* 6: 4823-4830, 2000.
23. Yan JW, Lin JS and He XX: The emerging role of miR-375 in cancer. *Int J Cancer* 135: 1011-1018, 2014.
24. Hui AB, Bruce JP, Alajez NM, Shi W, Yue S, Perez-Ordóñez B, Xu W, O'Sullivan B, Waldron J, Cummings B, *et al*: Significance of dysregulated metadherin and microRNA-375 in head and neck cancer. *Clin Cancer Res* 17: 7539-7550, 2011.
25. Wang Z, Hong Z, Gao F and Feng W: Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia. *Mol Cell Biochem* 383: 59-65, 2013.
26. Szczyrba J, Nolte E, Wach S, Kremmer E, Stöhr R, Hartmann A, Wieland W, Wullich B and Grässer FA: Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. *Mol Cancer Res* 9: 791-800, 2011.
27. Kinoshita T, Yip KW, Spence T and Liu FF: MicroRNAs in extracellular vesicles: Potential cancer biomarkers. *J Hum Genet*: Jul 7, 2016 (Epub ahead of print). doi: 10.1038/jhg.2016.87.
28. Yonemori K, Kurahara H, Maemura K and Natsugoe S: MicroRNA in pancreatic cancer. *J Hum Genet*: Jun 2, 2016. (Epub ahead of print). doi: 10.1038/jhg.2016.59.
29. Knäuper V, López-Otin C, Smith B, Knight G and Murphy G: Biochemical characterization of human collagenase-3. *J Biol Chem* 271: 1544-1550, 1996.
30. Vincenti MP and Brinckerhoff CE: Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: Integration of complex signaling pathways for the recruitment of gene-specific transcription factors. *Arthritis Res* 4: 157-164, 2002.
31. Etoh T, Inoue H, Yoshikawa Y, Barnard GF, Kitano S and Mori M: Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. *Gut* 47: 50-56, 2000.
32. Xu N, Zhang L, Meisgen F, Harada M, Heilborn J, Homey B, Grandér D, Stähle M, Sonkoly E and Pivarski A: MicroRNA-125b down-regulates matrix metalloproteinase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion. *J Biol Chem* 287: 29899-29908, 2012.
33. Wu D, Ding J, Wang L, Pan H, Zhou Z, Zhou J and Qu P: microRNA-125b inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in bladder cancer. *Oncol Lett* 5: 829-834, 2013.
34. Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T, *et al*: MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloproteinase-13 expression. *Mol Ther* 19: 1123-1130, 2011.
35. Liu J, Mao Y, Zhang D, Hao S, Zhang Z, Li Z and Li B: MiR-143 inhibits tumor cell proliferation and invasion by targeting STAT3 in esophageal squamous cell carcinoma. *Cancer Lett* 373: 97-108, 2016.
36. Yuen KW, Montpetit B and Hieter P: The kinetochore and cancer: What's the connection? *Curr Opin Cell Biol* 17: 576-582, 2005.
37. Sagona AP and Stenmark H: Cytokinesis and cancer. *FEBS Lett* 584: 2652-2661, 2010.
38. Rath O and Kozielski F: Kinesins and cancer. *Nat Rev Cancer* 12: 527-539, 2012.
39. Huszar D, Theoclitou ME, Skolnik J and Herbst R: Kinesin motor proteins as targets for cancer therapy. *Cancer Metastasis Rev* 28: 197-208, 2009.
40. Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, Eastham JA, Gopalan A, Pienta KJ, Shen MM, *et al*: Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. *Cancer Cell* 25: 638-651, 2014.
41. Zhu C, Zhao J, Bibikova M, Levenson JD, Bossy-Wetzel E, Fan JB, Abraham RT and Jiang W: Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. *Mol Biol Cell* 16: 3187-3199, 2005.
42. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS and Gallie BL: KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. *Clin Cancer Res* 13: 3229-3234, 2007.
43. Thériault BL, Pajovic S, Bernardini MQ, Shaw PA and Gallie BL: Kinesin family member 14: An independent prognostic marker and potential therapeutic target for ovarian cancer. *Int J Cancer* 130: 1844-1854, 2012.